Table 1 Characteristics of patients receiving ramosetron or placebo
Ramosetron (n = 51) | Placebo (n = 52) | |
|---|---|---|
Male sex | 42 (82.4 %) | 40 (76.9 %) |
Age (years) | 66.8 ± 9.4 | 66.0 ± 9.9 |
Weight (kg) | 66.0 ± 11.1 | 63.5 ± 10.3 |
Height (cm) | 164.5 ± 9.3 | 162.0 ± 8.2 |
Body mass index (kg/m2) | 24.4 ± 3.0 | 24.1 ± 3.0 |
Hypertension | 37 (72.5 %) | 33 (63.5 %) |
Diabetes mellitus | 22 (43.1 %) | 17 (32.7 %) |
1-Vessel disease | 0 (0.0 %) | 4 (7.7 %) |
2-Vessel disease | 6 (11.8 %) | 8 (15.4 %) |
3-Vessel disease | 45 (88.2 %) | 40 (76.9 %) |
Previous myocardial infarction | 3 (5.9 %) | 4 (7.7 %) |
Previous stroke | 3 (5.9 %) | 4 (7.7 %) |
Current smoker | 11 (21.6 %) | 9 (17.3 %) |
Sodium (mEq/l) | 138.6 ± 3.7 | 139.1 ± 2.9 |
Potassium (mEq/l) | 4.1 ± 0.4 | 4.0 ± 0.4 |
Bradycardia (heart rate <50 beats/min) | 2 (4.0 %) | 2 (3.9 %) |
Left ventricle ejection fraction | ||
> 49 % | 48 (94.1 %) | 48 (92.3 %) |
30–49 % | 3 (5.9 %) | 4 (7.7 %) |
< 30 % | 0 (0.0 %) | 0 (0.0 %) |
Preoperative QTc interval (ms) | 430.7 ± 33.6 | 425.2 (29.7) |
Preoperative QTc interval > 500 ms | 0 (0.0 %) | 0 (0.0 %) |
Congenital long QT syndrome | 0 (0.0 %) | 0 (0.0 %) |
Duration of anaesthesia (min) | 449.7 ± 44.2 | 451.4 ± 68.0 |